date:Aug 13, 2014
believe our ownership of these new patent rights creates a significant and meaningful barrier to entry for would-be competitors in the entire NAD+ precursor market.
- During the second quarter, ChromaDex announced separate material transfer and research agreements for its patented ingredient technologies with St. Jude Children's Research Hospital, Wageningen University in the Netherlands, the Novo Nordisk Foundation Center for Basic Metabolic Research at University of Copenhagen, Denmark, and Br